275 related articles for article (PubMed ID: 25698402)
21. Mucinous tumor of the appendix with limited peritoneal spread: is there a role for expectant observation?
Zih FS; Wong-Chong N; Hummel C; Petronis J; Panzarella T; Pollett A; McCart JA; Swallow CJ
Ann Surg Oncol; 2014 Jan; 21(1):225-31. PubMed ID: 24100959
[TBL] [Abstract][Full Text] [Related]
22. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
Taflampas P; Dayal S; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2014 May; 40(5):515-520. PubMed ID: 24462284
[TBL] [Abstract][Full Text] [Related]
23. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
[TBL] [Abstract][Full Text] [Related]
24. [Guest comment on the article: appendiceal mucoceles, pseudomyxoma peritonei, and appendiceal mucinous neoplasms. Update on the contribution of imaging to choice of the surgical approach, J.F. Gillion et al].
Goere D
J Chir (Paris); 2009 Apr; 146(2):167. PubMed ID: 19540495
[No Abstract] [Full Text] [Related]
25. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
26. Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative.
Zaidi MY; Lee RM; Gamboa AC; Speegle S; Cloyd JM; Kimbrough C; Grotz T; Leiting J; Fournier K; Lee AJ; Dineen S; Dessureault S; Kelly KJ; Kotha NV; Clarke C; Gamblin TC; Patel SH; Lee TC; Hendrix RJ; Lambert L; Ronnekleiv-Kelly S; Pokrzywa C; Blakely AM; Lee B; Johnston FM; Fackche N; Russell MC; Maithel SK; Staley CA
Ann Surg Oncol; 2020 Jan; 27(1):156-164. PubMed ID: 31602579
[TBL] [Abstract][Full Text] [Related]
27. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Iavazzo C; Spiliotis J
Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
[No Abstract] [Full Text] [Related]
28. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
29. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
Omohwo C; Nieroda CA; Studeman KD; Thieme H; Kostuik P; Ross AS; Holter DR; Gushchin V; Merriman B; Sardi A
J Am Coll Surg; 2009 Sep; 209(3):308-12. PubMed ID: 19717034
[TBL] [Abstract][Full Text] [Related]
30. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
[TBL] [Abstract][Full Text] [Related]
31. Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Mehta A; Mittal R; Chandrakumaran K; Carr N; Dayal S; Mohamed F; Moran B; Cecil T
Dis Colon Rectum; 2017 Nov; 60(11):1155-1161. PubMed ID: 28991079
[TBL] [Abstract][Full Text] [Related]
32. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
[TBL] [Abstract][Full Text] [Related]
33. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
[TBL] [Abstract][Full Text] [Related]
34. Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.
Ward EP; Okamuro L; Khan S; Hosseini M; Valasek MA; Ronquillo N; Kelly KJ; Veerapong J; Lowy AM; Baumgartner J
Hum Pathol; 2021 Jul; 113():104-110. PubMed ID: 33905776
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
[TBL] [Abstract][Full Text] [Related]
36. Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series.
Guaglio M; Sinukumar S; Kusamura S; Milione M; Pietrantonio F; Battaglia L; Guadagni S; Baratti D; Deraco M
Ann Surg Oncol; 2018 Apr; 25(4):878-884. PubMed ID: 29270877
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
38. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
39. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Randle RW; Griffith KF; Fino NF; Swett KR; Stewart JH; Shen P; Levine EA; Votanopoulos KI
J Surg Res; 2015 Jun; 196(2):229-34. PubMed ID: 25881787
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score.
Bouquot M; Dohan A; Gayat E; Barat M; Glehen O; Pocard M; Rousset P; Eveno C
Ann Surg Oncol; 2018 Mar; 25(3):694-701. PubMed ID: 29192372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
